D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $21.00 price target on the stock. D. Boral Capital’s price target suggests a potential upside of 217.70% from the stock’s previous close.

TRVI has been the subject of several other research reports. Needham & Company LLC decreased their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright lifted their price objective on Trevi Therapeutics from $7.50 to $12.50 and gave the stock a “buy” rating in a report on Monday, March 10th. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Finally, Oppenheimer lifted their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $17.56.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $6.61 on Wednesday. The stock has a market capitalization of $508.08 million, a price-to-earnings ratio of -15.02 and a beta of 0.90. Trevi Therapeutics has a one year low of $2.30 and a one year high of $7.39. The business’s fifty day moving average is $4.55 and its 200-day moving average is $3.73.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. Research analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Insider Buying and Selling at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares in the company, valued at approximately $519,075. This trade represents a 51.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 24.37% of the company’s stock.

Institutional Trading of Trevi Therapeutics

A number of large investors have recently modified their holdings of TRVI. GSA Capital Partners LLP bought a new stake in shares of Trevi Therapeutics during the 3rd quarter valued at about $409,000. Oppenheimer & Co. Inc. boosted its position in shares of Trevi Therapeutics by 34.7% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 81,947 shares of the company’s stock valued at $274,000 after acquiring an additional 21,128 shares during the last quarter. MAI Capital Management boosted its position in shares of Trevi Therapeutics by 0.7% during the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock valued at $4,433,000 after acquiring an additional 8,789 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Trevi Therapeutics during the 3rd quarter valued at about $63,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after acquiring an additional 6,764 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.